LAUSR

We read with great interest the series of letters regarding dolutegravir-related neuropsychiatric adverse events (NP-AE) [1–4]. We report, here, our experience in a French cohort, to add on the current debate. Data were obtained from electronic records of patients attending HIV services at Paris Seine-Saint-Denis Hospitals. We extracted data of patients who initiated dolutegravir and who discontinued the drug because of adverse events, focusing on NP-AE. We compared patients who received dolutegravir-containing regimens with and without abacavir. We used Pearson x test for statistical analysis.